What condition is Crysvita (burosumab-twza) used to treat?
Medically reviewed by Drugs.com Last updated on Oct 1, 2019.
Official Answerby Drugs.com
X-linked hypophosphatemia (XLH) leads to low phosphorus levels in the body and treatment with vitamin D is not effective for this type of rickets. Impaired bone growth in childhood and problems with bone mineralization can occur.
Crysvita (burosumab-twza) is classified as a fibroblast growth factor 23 (FGF23) blocking antibody. It is used to treat X-linked hypophosphatemia in adult and pediatric patients 6 months of age and older.